Compositions and methods of detecting tiabs
AssigneeTransmedi SA
InventorsBernard Bihain, Virginie Ogier, Marie Brulliard
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel methods and products for assessing the physiological status of a subject. More particularly, the invention relates to methods of assessing the presence, risk or stage of a cancer in a subject by measuring the levels of antibodies against particular aberrant protein domains in a sample from the subject, or the presence or number of immune cells bearing TCR specific for such aberrant protein domains. The invention is also suitable to assess the responsiveness of a subject to a treatment, as well as to screen candidate drugs and design novel therapies. The invention may be used in any mammalian subject, particularly in human subjects.
Claims20
1-37. (canceled)
A method for detecting the presence, risk or stage of development of a cancer in a subject, the method comprising contacting in vitro a sample from the subject with a polypeptide comprising the sequence of an aberrant protein domain created by transcription infidelity, wherein the formation of a complex between said polypeptide and an antibody (TIAB) or TCR-bearing cell present in said sample is an indication of the presence, risk or stage of development of a cancer.
A method of assessing the physiological status of a subject, the method comprising a step of measuring the presence or level of antibodies specific for aberrant protein domains created by transcription infidelity (TIAB) or of TCR-bearing immune cells that bind to such domains in a sample from the subject, wherein a modified level of said TIAB or immune cells in said sample as compared to a reference value is an indication of a physiological disorder.
A method of determining the efficacy of a treatment of a cancer, the method comprising (i) determining the level of at least one polypeptide comprising the sequence of an aberrant protein domain created by transcription infidelity or the level of TIAB or corresponding TCR-bearing cells, in a sample from the subject and (ii) comparing said level to the level in a sample from said subject taken prior to or at an earlier stage of the treatment.
A method of monitoring the progression or the extension of a cancer in a subject, said method comprising (i) contacting a sample obtained from said subject with at least one polypeptide comprising the sequence of an aberrant protein domain created by transcription infidelity, (ii) determining the level of TIAB or corresponding TCR-bearing cells in said sample and (iii) comparing said level to reference value, a variation is indicative of the progression or the extension of the cancer.
A method of determining whether an individual is making a polypeptide comprising a sequence selected from the group consisting of SEQ ID NOs:
- 1-3334, comprising contacting a sample obtained from said individual with an agent indicative of the presence of said polypeptide and determining whether said agent binds to said sample.
A composition of matter comprising:
- a) a polypeptide comprising a sequence selected from SEQ ID NOs:
- 1 to 3334 or an epitope-containing fragment thereof;
- b) an isolated polynucleotide encoding a polypeptide of a);
- c) a cloning or expression vector comprising a polynucleotide of c);
- d) an isolated cell transformed or transfected with a vector of c);
- e) an isolated antibody or portion of an antibody which specifically binds to a polypeptide selected from the group consisting of SEQ ID NOs:
- 1-3334;
- or
- f) a solid support comprising a molecule selected from:
- a) at least one antibody or portion of an antibody which specifically binds to a polypeptide selected from the group consisting of SEQ ID NOs:
- 1-3334;
- or b) at least one polypeptide comprising a sequence selected from SEQ ID NOs 1 to 3334 or an epitope-containing fragment thereof.
Dependencies are inferred from the claim text.